Vaccine Info

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine

Authored by
Staff
Last reviewed
April 15, 2021
Fact checked by
Robert Carlson, MD
Share

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine Description

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine candidate encodes for a prefusion F glycoprotein, which elicits a superior neutralizing antibody response. mRNA-1345 uses the same lipid nanoparticle (LNP) as Moderna’s authorized Covid-19 vaccine and contains optimized protein and codon sequences.

There is no FDA approved vaccine for RSV.

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine Indication

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine candidate is indicated to prevent illness from the Respiratory Syncytial Virus. RSV is the leading cause of respiratory illness in young children. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine News

April 14, 2021 - Moderna shared the first interim analysis of the Phase 1 study after 1-month post-vaccination of younger adults (18-49). 'mRNA-1345 was shown to increase RSV neutralizing antibodies in seropositive younger adults. Neutralizing antibodies were confirmed to be present at baseline in all participants, as expected. A single vaccination of mRNA-1345 at the 50 or 100 μg dose level boosted neutralizing antibody titers against both serotypes of RSV-A and RSV-B with no apparent dose-response. At month 1, the geometric mean fold rise in neutralizing antibody relative to baseline was at least 20.5 for RSV-A and at least 11.7 for RSV-B.'

mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine Clinical Trials

Clinical Trial NCT04528719: A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus Seropositive. Estimated Completion Date: September 30, 2023